Collaboration Agreement - Additional Information (Details) - USD ($) |
1 Months Ended | 12 Months Ended | |
|---|---|---|---|
Feb. 28, 2022 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Collaboration revenue | $ 398,000 | $ 1,534,000 | |
| Combined performance obligation | 8,400,000 | ||
| Development activities performance obligation | $ 3,600,000 | ||
| Revenue description | Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.4 million to the Combined Performance Obligation and $3.6 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.5 million to the Combined Performance Obligation and $1.5 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of December 31, 2025, as all milestone amounts were fully constrained based on the probability of achievement. | ||
| Clinical Supply Agreement | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Upfront payment recognition in future periods to settlement of obligation | $ 12,000,000 | ||
| Milestone Achievements | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Collaboration revenue | $ 5,000,000 | 0 | $ 0 |
| Upfront payment recognition in future periods to settlement of obligation | 5,000,000 | 5,000,000 | |
| Combined performance obligation | $ 3,500,000 | 3,489,000 | |
| Development activities performance obligation | 1,511,000 | ||
| Pre-Milestone | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Upfront payment recognition in future periods to settlement of obligation | 12,000,000 | ||
| Combined performance obligation | 8,373,000 | ||
| Development activities performance obligation | 3,627,000 | ||
| Post-Milestone | |||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | |||
| Upfront payment recognition in future periods to settlement of obligation | 17,000,000 | ||
| Combined performance obligation | 11,862,000 | ||
| Development activities performance obligation | $ 5,138,000 | ||